Analyst Price Targets — STXS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 5, 2025 9:23 am | — | UBS | $4.00 | $2.70 | TheFly | Stereotaxis resumed with a Buy at Roth Capital |
| June 23, 2022 7:31 am | Neil Chatterji | B.Riley Financial | $6.00 | $1.94 | Pulse 2.0 | Stereotaxis (STXS) Stock: Why It Increased Over 6% Today |
Latest News for STXS
STXS jumps on FDA clearance of Synchrony system, a 4K platform integrating cath lab tech with cloud connectivity to boost workflow, precision and digital surgery.
ST. LOUIS, April 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received U.S. Food and Drug Administration 510(k) clearance for the Synchrony™ system.
Stereotaxis targets early-stage endovascular robotics with differentiated magnetic navigation for electrophysiology and other minimally invasive procedures. Their MAGiC catheter recently received FDA approval, which I think strengthens STXS's razor-and-blade model by adding recurring disposable revenues. At this point, the bull case rests on STXS growing its early adoption into durable revenues across…
Stereotaxis, Inc. (STXS) Q4 2025 Earnings Call Transcript
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.06 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.09 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for STXS.
U.S. House Trading
No House trades found for STXS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.